Disease activity, autoantibodies, and inflammatory molecules in serum and cerebrospinal fluid of patients with Systemic Lupus Erythematosus and Cognitive Dysfunction

Objective To determine if cognitive dysfunction in patients with systemic lupus erythematosus (SLE) derives from an inflammatory process with continuing disease activity, and increased levels of autoantibodies and inflammatory molecules in serum and cerebrospinal fluid (CSF). Methods 100 randomly selected patients participating in an inception SLE cohort were studied. At entry into the cohort, a standardized medical history and extensive laboratory tests profile, including autoantibodies were completed. Follow-up occurred every 3–6 months with assessment of lupus characteristics, comorbidities, and treatment. After a mean follow-up of six-years, cross-sectional evaluation of cognitive function was done with standardized tests, and in a subset of patients an extended profile of autoantibodies, cytokines and chemokines was measured in serum and CSF. Results At enrollment into the cohort, patients were 26.4±8.2 years of age and lupus duration 5.3±3.7 months. Moderate/severe cognitive dysfunction was diagnosed in 16 patients; in comparison to patients with normal cognitive function, they had lower education 9 vs. 12 years (P = 0.006), higher body mass index 26.7 vs. 24.3 (P = 0.03), positive IgG anticardiolipin antibodies 50% vs 18% (P = 0.009), and a higher median number of concomitant NPSLE syndromes 3 vs. 1, (P = 0.04). The prevalence of cardiovascular-risk factors, other auto-antibodies, lupus activity, treatment, and incidence of critical events did not differ. In serum and CSF, the levels of autoantibodies, cytokines and chemokine were similar, only CCL2 was elevated in CSF [886.1 (374.9–1439.7) vs. 515.8 (3.2–1958.2) pg/mL, P = 0.04]. Conclusion Scant evidence of inflammation in SLE patients with cognitive dysfunction was observed. Only a higher prevalence of IgG anticardiolipin antibodies in serum and increased levels of CCL2 in CSF were detected.

[1]  Systemic Lupus Erythematosus Disease Activity Index , 2020, Definitions.

[2]  Y. Hayashi,et al.  Cerebrospinal Fluid C-C Motif Chemokine Ligand 2 Correlates with Brain Atrophy and Cognitive Impairment in Alzheimer's Disease. , 2017, Journal of Alzheimer's disease : JAD.

[3]  Jürgen Floege,et al.  The Montreal Cognitive Assessment (MoCA) - A Sensitive Screening Instrument for Detecting Cognitive Impairment in Chronic Hemodialysis Patients , 2014, PloS one.

[4]  J. Madrigal,et al.  The chemokine (C-C motif) ligand 2 in neuroinflammation and neurodegeneration. , 2014, Advances in experimental medicine and biology.

[5]  J. Sánchez-Guerrero,et al.  Inflammatory profile in cerebrospinal fluid of patients with headache as a manifestation of neuropsychiatric systemic lupus erythematosus. , 2013, Rheumatology.

[6]  G. Bernard,et al.  Long-term cognitive impairment after critical illness. , 2013, The New England journal of medicine.

[7]  Sara G. Murray,et al.  Cardiovascular disease and cognitive dysfunction in systemic lupus erythematosus , 2012, Arthritis care & research.

[8]  Oskar Hansson,et al.  CCL2 Is Associated with a Faster Rate of Cognitive Decline during Early Stages of Alzheimer's Disease , 2012, PloS one.

[9]  S. Zeger,et al.  Cognitive and neurologic outcomes after coronary-artery bypass surgery. , 2012, The New England journal of medicine.

[10]  D. Gladman,et al.  The Systemic Lupus International Collaborating Clinics (SLICC) Group – It Was 20 Years Ago Today , 2012 .

[11]  C. Aguilar-Salinas,et al.  Systemic lupus erythematosus risk factors for coronary artery calcifications. , 2012, Rheumatology.

[12]  L. Minthon,et al.  CCL 2 Is Associated with a Faster Rate of Cognitive Decline during Early Stages of Alzheimer ’ s Disease , 2012 .

[13]  D. Gladman,et al.  The Systemic Lupus International Collaborating Clinics (SLICC) group – It was 20 years ago today , 2011, Lupus.

[14]  D. Gladman,et al.  Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus , 2010, Arthritis care & research.

[15]  I. Bruce,et al.  Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus , 2009, Annals of the rheumatic diseases.

[16]  D. Arciniegas,et al.  White Matter Microstructure and Cognition in Non-neuropsychiatric Systemic Lupus Erythematosus , 2009, Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology.

[17]  V. Gudnason,et al.  American Journal of Epidemiology Original Contribution Cognitive Impairment: an Increasingly Important Complication of Type 2 Diabetes the Age, Gene/environment Susceptibility–reykjavik Study , 2022 .

[18]  J. Sánchez-Guerrero,et al.  Serum and Cerebrospinal Fluid Autoantibodies in Patients with Neuropsychiatric Lupus Erythematosus. Implications for Diagnosis and Pathogenesis , 2008, PloS one.

[19]  K. Heilman,et al.  Predictors of Cognitive Dysfunction after Major Noncardiac Surgery , 2008, Anesthesiology.

[20]  S. D'agostini,et al.  General and specific factors associated with severity of cognitive impairment in systemic lupus erythematosus. , 2007, Arthritis and rheumatism.

[21]  L. Trupin,et al.  Impact of memory impairment on employment status in persons with systemic lupus erythematosus. , 2007, Arthritis and rheumatism.

[22]  J. Sánchez-Guerrero,et al.  Interleukin-6 and chemokines in the neuropsychiatric manifestations of systemic lupus erythematosus. , 2007, Arthritis and rheumatism.

[23]  B. Volpe,et al.  Human lupus autoantibodies against NMDA receptors mediate cognitive impairment , 2006, Proceedings of the National Academy of Sciences.

[24]  J. Ruidavets,et al.  Relation between body mass index and cognitive function in healthy middle-aged men and women , 2006, Neurology.

[25]  M. Lockshin,et al.  Relationship between serum NR2a antibodies and cognitive dysfunction in systemic lupus erythematosus. , 2006, Arthritis and rheumatism.

[26]  B. Volpe,et al.  Anti-N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. , 2006, Arthritis and rheumatism.

[27]  T. Yoshio,et al.  Association of IgG anti-NR2 glutamate receptor antibodies in cerebrospinal fluid with neuropsychiatric systemic lupus erythematosus. , 2006, Arthritis and rheumatism.

[28]  D. Arciniegas,et al.  Cognition, MRS Neurometabolites, and MRI Volumetrics in Non-Neuropsychiatric Systemic Lupus Erythematosus: Preliminary Data , 2005, Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology.

[29]  Li Min Li,et al.  Cerebral and corpus callosum atrophy in systemic lupus erythematosus. , 2005, Arthritis and rheumatism.

[30]  D. Gladman,et al.  Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE. , 2005, The Journal of rheumatology.

[31]  J. Mikdashi,et al.  Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort. , 2004, Rheumatology.

[32]  C. Björkelund,et al.  A 24-year follow-up of body mass index and cerebral atrophy , 2004, Neurology.

[33]  E A Wright,et al.  Validation of a systemic lupus activity questionnaire (SLAQ) for population studies , 2003, Lupus.

[34]  G. Gronseth,et al.  Neuropsychiatric syndromes in lupus: Prevalence using standardized definitions , 2002, Neurology.

[35]  D. Gladman,et al.  Systemic lupus erythematosus disease activity index 2000. , 2002, The Journal of rheumatology.

[36]  B. Diamond,et al.  A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus , 2001, Nature Medicine.

[37]  J. Peltola,et al.  The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus , 2001, Neurology.

[38]  A. Folsom,et al.  Cardiovascular risk factors and cognitive decline in middle-aged adults , 2001, Neurology.

[39]  Caroline Gordon,et al.  The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. , 1999, Arthritis and rheumatism.

[40]  J. Fisk,et al.  A prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus. , 1999, Arthritis and rheumatism.

[41]  D. Isenberg,et al.  A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. , 1999, Arthritis and rheumatism.

[42]  D. Gladman,et al.  Pattern of neuropsychologic dysfunction in inactive systemic lupus erythematosus. , 1997, Neuropsychiatry, neuropsychology, and behavioral neurology.

[43]  M. Hochberg,et al.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.

[44]  S. West,et al.  Analysis of cognitive and psychological deficits in systemic lupus erythematosus patients without overt central nervous system disease. , 1996, Arthritis and rheumatism.

[45]  D. Symmons,et al.  The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. , 1996, Arthritis and rheumatism.

[46]  M. Liang,et al.  A controlled study of the prevalence of cognitive dysfunction in randomly selected patients with systemic lupus erythematosus. , 1992, Arthritis and rheumatism.

[47]  J. Fisk,et al.  Cognitive impairment in patients with systemic lupus erythematosus. , 1992, The Journal of rheumatology.

[48]  J. Denburg,et al.  Cognitive impairment in systemic lupus erythematosus: a neuropsychological study of individual and group deficits. , 1987, Journal of clinical and experimental neuropsychology.

[49]  J. Denburg,et al.  Prevalence of Cognitive Impairment in Systemic Lupus Erythematosus , 1986, The Journal of nervous and mental disease.

[50]  J F Fries,et al.  The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.